Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference
Aug/110
ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of the company’s business activities and financial performance.
A webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions, led by Chairman and CEO Fuad El-Hibri, protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Aug/090
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri - Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt – Cowen & Company
David Moskowitz – Caris & Company
Mona Ashiya – J.P. Morgan
Sean Long – Kennedy Capital Management
Presentation
Operator
Welcome to the Emergent BioSolutions Incorporated second quarter 2009 financial results conference call. (Operator Instructions) I would now like to turn the call over to Mr. Robert Burrows.
Robert Burrows
Good afternoon ladies and gentlemen. My name is Robert Burrows, Vice President of Investor Relations for Emergent. Thank you for joining us today as we discuss Emergent BioSolutions financial results for the second quarter and first six months of 2009. As is customary, our call today is open to all participants. In addition, the call is being recorded and is copyrighted by Emergent BioSolutions.
Pages
Categories
- Abdul Aziz Said
- Anthrax
- Arab
- Atlanta
- BARDA
- BioDefense
- Biothrax
- Board of directors
- Business
- Chief executive officer
- Chief financial officer
- Chief Medical Officer
- Chief operating officer
- Clinical trial
- Disease Control and Prevention
- Dr. Mary Elizabeth King
- El-Hibri
- El-Hibri Peace Education Prize
- Emergent BioSolutions
- Entrepreneur
- Ernst & Young
- Financial Performance
- Food and Drug Administration
- Fuad El-Hibri
- Health Care Reform
- Healthcare
- Healthcare Conference
- Hudson Institute
- Infectious disease
- Investor relations
- Investors
- Leadership
- Music
- National Health Museum
- NATO
- North Atlantic Treaty Organization
- NuThrax
- NYSE
- Research and development
- Revenue
- Scholars Program
- Seattle
- Shareholder
- South Africa
- Tech Council of Maryland
- Trubion Pharmaceuticals
- U.S. Food and Drug Administration
- Uncategorized
- United States
- United States Department of Defense
- Vaccine
- Washington Metropolitan Area
- Webcast
- World TB Day
- Yale University
Archive
- February 2012
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- January 2010
- December 2009
- October 2009
- August 2009
- July 2009
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=c5ab759c-072f-42a9-aa99-baa48c935ec4)